Andrew Gengos Spends US$192k On Athira Pharma Stock \
Potential Athira Pharma, Inc. (NASDAQ:ATHA) shareholders may wish to note that the CFO & Chief Business Officer, Andrew Gengos, recently bought US$192k worth of stock, paying US$2.95 for each share. However, it only increased shareholding by a small percentage, and it wasn't a huge purchase by absolute value, either.
Check out our latest analysis for Athira Pharma
Athira Pharma Insider Transactions Over The Last Year
Notably, that recent purchase by Andrew Gengos is the biggest insider purchase of Athira Pharma shares that we've seen in the last year. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$3.59. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.
Happily, we note that in the last year insiders paid US$550k for 190.01k shares. On the other hand they divested 20.00k shares, for US$54k. Overall, Athira Pharma insiders were net buyers during the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
Athira Pharma is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.
Insider Ownership Of Athira Pharma
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. I reckon it's a good sign if insiders own a significant number of shares in the company. Our data indicates that Athira Pharma insiders own about US$9.6m worth of shares (which is 7.0% of the company). We do generally prefer see higher levels of insider ownership.
What Might The Insider Transactions At Athira Pharma Tell Us?
The recent insider purchases are heartening. We also take confidence from the longer term picture of insider transactions. But on the other hand, the company made a loss during the last year, which makes us a little cautious. On this analysis the only slight negative we see is the fairly low (overall) insider ownership; their transactions suggest that they are quite positive on Athira Pharma stock. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. To that end, you should learn about the 3 warning signs we've spotted with Athira Pharma (including 2 which can't be ignored).
But note: Athira Pharma may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here
